Skip to Content

Posts tagged with "Drug Development"

  • Drug Development

    How Long Can This Go On?

    Back before my vacation, I mentioned the problem of judging how long a drug project should be allowed to run. You have to call a halt eventually, because it’s very rare for a project to finish of its own accord – by which I mean “arrive at a conclusion that no one can argue about… Read More
  • Diabetes and Obesity

    Worries about Rimonabant?

    Continuing on the theme of unexpected toxicity landmines, I wanted to take a look at a highly anticipated obesity drug from Sanofi. Rimonabant is a small molecule antagonist of the CB-1 receptor, and it’s been getting a lot of press – both for its impressive efficacy and for its mechanism of action. The “CB” in… Read More
  • Cancer

    Bungee Jumping with PPAR Drugs

    The PPAR family (known in the US as alpha, gamma, and delta, for obscure historical reasons) is one of those biological jungles that keep us all employed. They’re nuclear receptors, and thus they’re involved in up- and down-regulation of hundreds of genes. Like most of the other nuclear receptors, they do that by responding to… Read More
  • Drug Development

    The Two Ends of the Stick

    I wanted to emphasize a point I made yesterday, about how far removed the research organization is from the sales force in a drug company. I’m not backing away from them, just pointing out that we’re at completely opposite ends of a company’s functions. By the time a drug gets into the hands of the… Read More
  • Drug Development

    Down the Hatch

    We have a lot of received wisdom in the drug business, rules of thumb and things that everybody knows. One of the things that we all know is that the gut wall isn’t much fun for our drugs to get across sometimes. That’s inconvenient, since most people would prefer to swallow their medicine rather than… Read More
  • Drug Assays

    What Ails Us

    Before getting started, I’d like to recommend the discussion going on in the Comments section of the “All the Myriad Ways” post below. If you find the topic of gene patents at all interesting, it’s worth keeping up with. Me, I’m just watching for now, feeling like Teresa Nielsen Hayden as the discussion takes off… Read More
  • Drug Development

    Odd Elements in Drugs: Silicon

    Another chemical element that you don’t see much in pharmaceuticals is silicon. Hey, it’s right under carbon in the periodic table, and forms four tetrahedral bonds just like carbon does, so why not, eh? Now, if you’re like me, you grew up reading old science fiction stories that posited silicon-based life forms. That seemed prett… Read More
  • Biological News

    The Vapor Trail I Referred To

    I mentioned the other day that not everything in that Stuart Schreiber interview sounded sane to me, (although more of it does than I’d expected). The interviewer, Joanna Owens, asks him to expand on a statement he made about ten years ago: famously (in some circles, at any rate) Schreiber said that he wanted to… Read More
  • Academia (vs. Industry)

    Stuart Schreiber on Stuart Schreiber

    The April issue of Drug Discovery Today has an intriguing interview (PDF file) with Stuart Schreiber of Harvard. Schreiber is an only partially human presence in the field, as a listing of his academic appointments will make clear: chairman, with an endowed professorship, of the Department of Chemistry at Harvard, investigator at the Howard Hughes… Read More
  • Drug Development

    The March of Folly Leader Board

    The first comment to the original March of Folly post below mirrors the e-mail I’ve received: the people’s choice for the technology most-likely-to-be-embarrassing is. . .(rustling of envelope): RNA interference. There’s a good case to be made for that, and it doesn’t contradict my oft-stated opinion that RNAi is going to be… Read More
...535455...